Search
Rapacuronium
go.drugbank.com/drugs/DB04834ApprovedWithdrawnRapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Glyceraldehyde-3-Phosphate Dehydrogenase
go.drugbank.com/drugs/DB17012ExperimentalCategories: Oxidoreductases Acting on Aldehyde or Oxo Group DonorsCol-118
go.drugbank.com/drugs/DB05778InvestigationalCOL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. … It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
MCC
go.drugbank.com/drugs/DB05282InvestigationalThe product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec. … Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria.
Ertumaxomab
go.drugbank.com/drugs/DB18923InvestigationalErtumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).
R411
go.drugbank.com/drugs/DB05468ExperimentalR411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.
Nialamide
go.drugbank.com/drugs/DB04820ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Synonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamideCategories: Monoamine Oxidase Inhibitors, Non-SelectiveBethanechol
go.drugbank.com/drugs/DB01019ApprovedBethanechol is a synthetic ester that was initially synthesized in 1935. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]
Synonyms: 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminiumReviparin
go.drugbank.com/drugs/DB09259Approved[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]
Cofirasersen
go.drugbank.com/drugs/DB19037InvestigationalCofirasersen is under investigation in clinical trial NCT04441788 (A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary